Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

Highly Accurate Detection of Circulating Tumor DNA for Monitoring Minimal Residual Disease in Solid Tumors: Analytical and Clinical Validation of the Haystack MRD Assay.

The paper reports analytical and clinical validation of the Haystack MRD assay for detecting rare ctDNA fragments among cell-free DNA.

The Journal of Molecular DiagnosticsPubMed 42624249DOI 10.1016/j.jmoldx.2026.07.006